论文部分内容阅读
[目的]观察加巴喷丁与胃复安辅助控制化疗后恶心呕吐的临床疗效。[方法]56例患者计划接受中高度致吐风险的化疗,所有患者随机分为A、B两组,第1个周期化疗A组患者接受胃复安方案(托烷司琼+地塞米松+胃复安),B组患者接受加巴喷丁方案(托烷司琼+地塞米松+加巴喷丁)进行止吐治疗;第2个周期化疗A、B两组患者交换止吐治疗方案,评估急性期(化疗后24h)和延迟期(化疗后24~120h)的恶心呕吐控制率。[结果]急性期恶心完全缓解率加巴喷丁方案和胃复安方案分别为53.57%和16.07%(P<0.05),急性期呕吐的完全缓解率分别51.79%和33.93%(P>0.05);在延迟期,恶心的完全缓解率分别为51.79%和23.21%(P<0.05),呕吐的完全缓解率分别为57.14%和30.36%(P<0.05)。两种方案不良反应无差异。[结论]加巴喷丁作为辅助性止吐治疗药物明显减轻患者化疗后恶心呕吐,疗效明显优于胃复安。
[Objective] To observe the clinical efficacy of gabapentin and metoclopramide in the control of nausea and vomiting after chemotherapy. [Methods] Fifty-six patients were enrolled in this study. All patients were randomly divided into A and B groups. Patients in the first cycle of chemotherapy group A received metocloptin (tropisetron + dexamethasone + Metoclopramide), patients in group B received gabapentin regimen (tropisetron + dexamethasone + gabapentin) for antiemetic therapy; patients in groups A and B were given antiemetic regimens in the second cycle of chemotherapy and were evaluated for acute phase (chemotherapy After 24h) and delayed (24 ~ 120h after chemotherapy) nausea and vomiting control rate. [Results] The complete response rates of gabapentin and metoclopramide were 53.57% and 16.07% respectively in acute phase (P <0.05), and 51.79% and 33.93% (P> 0.05) in complete remission of acute nausea respectively. The complete remission rates of stage and nausea were 51.79% and 23.21%, respectively (P <0.05). The complete remission rates of vomiting were 57.14% and 30.36% (P <0.05). Two programs no difference in adverse reactions. [Conclusion] Gabapentin as an adjunct antiemetic therapy significantly reduces nausea and vomiting in patients after chemotherapy, and the curative effect is obviously superior to metoclopramide.